All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,040.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration July 21, 2020
Details:
Under the terms of the agreement, Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience, which Roche will further develop and commercialize exclusively.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NK cell Engager Therapies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: Undisclosed Upfront Cash: $55.0 million
Deal Type: Licensing Agreement July 06, 2020
Details:
Under the agreement, Dragonfly will grant Bristol Myers Squibb the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary platform for multiple new targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tecovirimat
Therapeutic Area: Immunology Product Name: Tpoxx
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $414.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 25, 2020
Details:
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the deliveries of oral TPOXX® (tecovirimat) to the U.S. Department of Health and Human Services (HHS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tecovirimat
Therapeutic Area: Immunology Product Name: Tpoxx
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: JPEO-CBRND
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 15, 2020
Details:
Funding will support work necessary to gain a potential label expansion from the U.S. FDA for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: S.R. One
Deal Size: $65.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 21, 2020
Details:
The Series B financing will support the advancement of HotSpot’s lead programs to the clinic, including protein kinase C (PKC-theta) antagonists for Th2 and T-reg driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Synthetic AAV capsids Proteins
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Details:
The presentation will highlight results from Dyno's study on Artificial intelligence powered design of synthetic AAV capsids without pre-existing immunity for the universal treatment of all patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 06, 2020
Details:
Proceeds will be used to advance three pipeline programs and to expand the company’s structural immunology platform to pursue previously intractable drug targets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 27, 2020
Details:
The funding will support company's lead therapeutic approach that inhibits Gasdermin D, which has been recently discovered as a key target at the core of multiple inflammatory cell death pathways.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibodies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Pandion Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2020
Details:
Under the agreement, Pandion will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
